Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.01 0.25 (2.13%) Market Cap: 527.03 Mil Enterprise Value: 442.37 Mil PE Ratio: 0 PB Ratio: 5.31 GF Score: 56/100

Full Year 2020 Y-mAbs Therapeutics, Inc Earnings Call Transcript

Feb 26, 2021 / 02:00PM GMT
Release Date Price: $35.17 (+4.42%)
Operator

Greetings, and welcome to Y-mAbs' Fourth Quarter and Full Year 2020 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Thomas Gad, Chairman of Y-mAbs. Thank you, sir. You may begin.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President and Head of Business Development & Strategy

Thank you, and thank you, everyone. Good morning, and thank you for joining us today. So 2020 was the year that we believe was truly transformational for Y-mAbs as we became a commercial stage company. We've made significant progress on executing our strategy and expanding significantly on our 3 pillars of business: first, our leading monoclonal antibodies, DANYELZA and omburtamab; second, our bispecific compounds under the Y-BICLONE tech platform; and finally, the SADA technology platform.

As you know, we received U.S. approval for DANYELZA in primary refractory and relapsed high retinoblastoma on November 25, 2020. And from the beginning of February, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot